Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13D/A

Bolt Biotherapeutics, Inc.

BOLTNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Feb 17, 2026Accepted Feb 17, 2026, 3:11 PM ESTFiling CIK 1695076Accession 0001012975-26-000173
Share

Structured filing — SCHEDULE 13D/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
Bolt Biotherapeutics, Inc.
Company CIK
0001641281
Street
900 Chesapeake Drive
City
Redwood City
State / country code
CA
Postal code
94063

Statement details

Amendment number
3
Security class
Common Stock, $0.00001 par value
Event date
02/05/2026
Previously filed indication
false

Authorized notification person 1

Name
Robert Hopfner
Phone
(415) 697-1002
Street
Pivotal bioVenture Partners Fund I UGP
Street (continued)
501 2nd Street, Suite 200
City
San Francisco
State / country code
CA
Postal code
94107

Authorized notification person 2

Name
Louis Rambo
Phone
(202) 416-6800
Street
Proskauer Rose, LLP
Street (continued)
1001 Pennsylvania Avenue NW, Suite 600
City
Washington
State / country code
DC
Postal code
20004-2533

Reporting person 1

Name
Nan Fung Group Holdings Limited
Reporting person CIK
0001782539
No reporting person CIK indication
N
Citizenship / organization
D8
Reporting person type
CO
Group designation
b
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
128,119
Percent of class
6.7
Sole voting power
0
Shared voting power
128,119
Sole dispositive power
0
Shared dispositive power
128,119
Aggregate excludes certain shares
N

Reporting person 2

Name
NF Investment Holdings Limited
No reporting person CIK indication
Y
Citizenship / organization
D8
Reporting person type
CO
Group designation
b
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
128,119
Percent of class
6.7
Sole voting power
0
Shared voting power
128,119
Sole dispositive power
0
Shared dispositive power
128,119
Aggregate excludes certain shares
N

Reporting person 3

Name
Pivotal bioVenture Partners Fund I, L.P.
Reporting person CIK
0001695076
No reporting person CIK indication
N
Citizenship / organization
E9
Reporting person type
PN
Group designation
b
Source of funds code
WC
Legal proceedings indication
N
Aggregate amount owned
78,445
Percent of class
4.1
Sole voting power
0
Shared voting power
78,445
Sole dispositive power
0
Shared dispositive power
78,445
Aggregate excludes certain shares
N

Reporting person 4

Name
Pivotal bioVenture Partners Fund I G.P., L.P.
Reporting person CIK
0001752862
No reporting person CIK indication
N
Citizenship / organization
E9
Reporting person type
PN
Group designation
b
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
78,445
Percent of class
4.1
Sole voting power
0
Shared voting power
78,445
Sole dispositive power
0
Shared dispositive power
78,445
Aggregate excludes certain shares
N

Reporting person 5

Name
Pivotal bioVenture Partners Fund I U.G.P. Ltd.
No reporting person CIK indication
Y
Citizenship / organization
E9
Reporting person type
CO
Group designation
b
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
78,445
Percent of class
4.1
Sole voting power
0
Shared voting power
78,445
Sole dispositive power
0
Shared dispositive power
78,445
Aggregate excludes certain shares
N

Reporting person 6

Name
Pivotal Partners Ltd
No reporting person CIK indication
Y
Citizenship / organization
E9
Reporting person type
CO
Group designation
b
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
78,445
Percent of class
4.1
Sole voting power
0
Shared voting power
78,445
Sole dispositive power
0
Shared dispositive power
78,445
Aggregate excludes certain shares
N

Reporting person 7

Name
Pivotal Life Sciences Holdings Limited
No reporting person CIK indication
Y
Citizenship / organization
E9
Reporting person type
CO
Group designation
b
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
78,445
Percent of class
4.1
Sole voting power
0
Shared voting power
78,445
Sole dispositive power
0
Shared dispositive power
78,445
Aggregate excludes certain shares
N

Reporting person 8

Name
Nan Fung Life Sciences Holdings Limited
No reporting person CIK indication
Y
Citizenship / organization
D8
Reporting person type
CO
Group designation
b
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
123,119
Percent of class
6.4
Sole voting power
0
Shared voting power
123,119
Sole dispositive power
0
Shared dispositive power
123,119
Aggregate excludes certain shares
N

Reporting person 9

Name
Permwell Management Limited
No reporting person CIK indication
Y
Citizenship / organization
E9
Reporting person type
CO
Group designation
b
Source of funds code
WC
Legal proceedings indication
N
Aggregate amount owned
5,000
Percent of class
0.3
Sole voting power
0
Shared voting power
5,000
Sole dispositive power
0
Shared dispositive power
5,000
Aggregate excludes certain shares
N

Reporting person 10

Name
NFLS Beta Limited
No reporting person CIK indication
Y
Citizenship / organization
D8
Reporting person type
CO
Group designation
b
Source of funds code
WC
Legal proceedings indication
N
Aggregate amount owned
44,674
Percent of class
2.3
Sole voting power
0
Shared voting power
44,674
Sole dispositive power
0
Shared dispositive power
44,674
Aggregate excludes certain shares
N

Reporting person 11

Name
NFLS Platform Holdings Limited
No reporting person CIK indication
Y
Citizenship / organization
E9
Reporting person type
CO
Group designation
b
Source of funds code
WC
Legal proceedings indication
N
Aggregate amount owned
44,674
Percent of class
2.3
Sole voting power
0
Shared voting power
44,674
Sole dispositive power
0
Shared dispositive power
44,674
Aggregate excludes certain shares
N

Item 1

Issuer

Bolt Biotherapeutics, Inc.

Security title

Common Stock, $0.00001 par value

Principal address

Item 5

Number of shares

The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.

Transactions

Except as set forth on Schedule A, which is incorporated into this Item 5(c) by reference, no Reporting Person has effected any transaction in shares of Common Stock in the past sixty days.

Percentage of class

Items 5(a)-(c) of the Schedule 13D are amended and restated as follows: The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 1,919,441 outstanding shares of Common Stock, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025. In addition, Mr. Kam Chung Leung directly owns 8,684 shares of Common Stock.

Signature 1

Reporting person
Nan Fung Group Holdings Limited
Signed
/s/ Tang Chun Wai Nelson
Title
Tang Chun Wai Nelson, Director
Date
02/17/2026

Signature 2

Reporting person
NF Investment Holdings Limited
Signed
/s/ Tang Chun Wai Nelson
Title
Tang Chun Wai Nelson, Director
Date
02/17/2026

Signature 3

Reporting person
Pivotal bioVenture Partners Fund I, L.P.
Signed
By Pivotal bioVenture Partners Fund I G.P., L.P. · By Pivotal bioVenture Partners Fund I U.G.P., Ltd. · /s/ Robert Hopfner
Title
its General Partner · its General Partner · Robert Hopfner, Authorized Signatory
Date
02/17/2026 · 02/17/2026 · 02/17/2026

Signature 4

Reporting person
Pivotal bioVenture Partners Fund I G.P., L.P.
Signed
By Pivotal bioVenture Partners Fund I U.G.P., Ltd. · /s/ Robert Hopfner
Title
its General Partner · Robert Hopfner, Authorized Signatory
Date
02/17/2026 · 02/17/2026

Signature 5

Reporting person
Pivotal bioVenture Partners Fund I U.G.P. Ltd.
Signed
/s/ Robert Hopfner
Title
Robert Hopfner, Authorized Signatory
Date
02/17/2026

Signature 6

Reporting person
Pivotal Partners Ltd
Signed
/s/ Sun Xintong
Title
Sun Xintong, Director
Date
02/17/2026

Signature 7

Reporting person
Pivotal Life Sciences Holdings Limited
Signed
/s/ Sun Xintong
Title
Sun Xintong, Director
Date
02/17/2026

Signature 8

Reporting person
Nan Fung Life Sciences Holdings Limited
Signed
/s/ Sun Xintong
Title
Sun Xintong, Director
Date
02/17/2026

Signature 9

Reporting person
Permwell Management Limited
Signed
/s/ Tang Chun Wai Nelson
Title
Tang Chun Wai Nelson, Director
Date
02/17/2026

Signature 10

Reporting person
NFLS Beta Limited
Signed
/s/ Sun Xintong
Title
Sun Xintong, Director
Date
02/17/2026

Signature 11

Reporting person
NFLS Platform Holdings Limited
Signed
/s/ Sun Xintong
Title
Sun Xintong, Director
Date
02/17/2026

Filed exhibits

Company context

Bolt Biotherapeutics is a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Through the proprietary INSPIRE platform it acquired from Prana Therapies, the company combines complementary therapeutic mechanisms in fully IgG-based molecules designed for differentiated efficacy, extended exposure, and convenient dosing.

Current securities

Recent company filings

  1. 10-Q filingNov 13, 2026
  2. Results of Operations and Financial ConditionNov 12, 2026
  3. SCHEDULE 13G/A - filed by RENAISSANCE TECHNOLOGIES LLC regarding Bolt Biotherapeutics, Inc.Nov 12, 2026
  4. 4 filingOct 27, 2026
  5. 3 filingOct 27, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.